30 Jan

AMC Hosts Sensory-Friendly Films in Partnership with Autism Society

AMC Theatres brings sensory-friendly films to families affected by autism and related disorders, such as Angelman syndrome, on a monthly basis to select communities. The Sensory-Friendly Films program provides a special opportunity for families to enjoy their favorite films in a safe and accepting environment. The auditoriums dedicated to the program have their lights up, the sound turned down, and audience members are invited to get up and dance, walk, shout or sing!

Films include the latest releases and other films, and are typically hosted once a month at nearly 100 theatres across the country. All showings are at 10:00am local time on Saturdays.

See the schedule of upcoming films and participating AMC theatres.

08 Dec

Research Investigates Health Issues in Adults with Angelman Syndrome

Dr. Ron Thibert, the well-known Angelman syndrome clinician and champion of the low-glycemic index dietary seizure treatment, and Dr. Anna Larson, both of Massachusetts General Hospital, published the findings from their clinical investigation into health issues that adults with AS experience.

The research team conducted standardized phone interviews with caregivers for 110 adolescents and adults with AS aged 16 to 50 years old. The impact of age, gender, and genotype on specific outcomes in neurology, orthopedics, internal medicine, and psychiatry were investigated, but did not address treatment. Further work should continue to refine the observable characteristics of older individuals with AS. Primary areas of clinical management identified in this research include seizures, sleep, aspiration risk, GERD, constipation, dental care, vision, obesity, scoliosis, bone density, mobility, communication, behavior, and anxiety.

The following is a summary of their findings.

Active Seizures

  • Present in 41% of individuals
  • Epilepsy severity may assume a bimodal age distribution: seizures are typically most severe in early childhood but may recur in adulthood

Sleep Dysfunction

  • Present in 72% of individuals
  • Late-adolescent and adult sleep patterns are improved when compared to the degree of sleep dysfunction present during infancy and childhood
  • However, prevalence of poor sleep in adults remains quite high

Significant Constipation

  • Present in 85% of individuals

Overweight / Obesity

  • Present in 32% of individuals, with obesity disproportionately affecting women


  • Affects 50% of individuals with an average age of diagnosis at 12 years old
  • 24% of those diagnosed with scoliosis required surgery, an intervention disproportionately affecting men


  • 68% are able to walk independently


  • 13% are able to speak 5 or more words

Self-Injurious Behavior

  • 52% of individuals exhibit self-injurious behavior

Click here to access the American Journal of Medical Genetics paper.


01 Dec

ASF-Funded Research Discovers Possible Therapeutic for Angelman Syndrome

Promising ASF-funded research continues to move closer toward possible clinical trials, as announced today in a paper in Nature by Dr. Art Beaudet and his research team at Baylor College of Medicine.

The ASF funded this research in its 2011 and 2013 research grant cycles, as part of its $8 million and growing investment in AS research with the ultimate goal of finding a cure for AS.

More research will be conducted but pre-clinical trials in AS mice have proven that the paternal copy of Ube3a can be activated and that AS symptoms can be recovered, though more testing is needed to determine exactly how the cognitive deficits associated with AS are recovered.

Dan Harvey, chairman of the ASF’s Scientific Advisory Committee, has interpreted the research for AS families and developed the following summary about the research.

Neurotypical individuals have two versions of the Angelman syndrome gene (UBE3A), one from their mother (the maternal copy) and one from their father (the paternal copy) but only the one from the mother is expressed or “active.” In Angelman syndrome, the maternal copy is missing (deleted) or altered in some way to render it inactive. In 2008, Goal #1 of the ASF Research Roadmap was to aggressively explore activation of the silenced or “inactive” paternal copy of the AS gene (UBE3A) as a potential treatment for Angelman syndrome. The studies described in this article for Nature are the culmination of those efforts.

Recent studies by Philpot and colleagues demonstrated that Topotecan, a natural product derivative with various uses, unsilences the paternal copy of the AS gene in a non-specific manner. In this new article for Nature by Dr. Beaudet, Dr. Meng and their colleagues, it is demonstrated that a small DNA analog, known as an antisense oligonucleotide or ASO, can interact with the paternal copy of the AS gene and unsilence it in a highly specific manner.

Initial studies done with isolated neurons demonstrated that treatment with an ASO causes a long-lasting unsilencing of the paternal copy of the Ube3a gene.

Subsequent studies were done with AS mice. The ASO was directly injected into the brain of an AS mouse via a technique known as ICV (intracerebroventricular) injection. The ASO was well tolerated and partially unsilenced the paternal copy of the Ube3a gene. Additionally, it was highly specific for the AS gene, with no impact on other genes. Its activity was long lasting with unsilencing still observed sixteen weeks after treatment. When injected directly into a specific region of the brain know as the hippocampus, the part of the brain that manages cognition and learning, complete unsilencing of the paternal Ube3a was observed in the vicinity of the injection site.

Four weeks after treatment, AS mice treated with an ASO were subjected to behavioral testing and several of the behaviors typically observed in AS mice were reversed. In particular, memory impairment observed with AS mice was reversed after treatment. More extensive reversal of AS characteristics may require treatment at a younger age, a longer recovery time after treatment to allow greater rewiring of neural circuits, or a higher dosage of ASO.

In conclusion, the paper states: “Well tolerated delivery, broad tissue distribution, and long duration of action sets a framework for ASOs as a viable therapeutic strategy for diseases of the CNS (central nervous system), and builds enthusiasm toward further optimization and development of an ASO treatment for AS.”

View information about this study on Nature Journal of Science website. 

17 Nov

PNAS Paper shows ASF-funded Research at UNC Making Progress

The ASF continues to lead the charge in funding research that is making progress towards treatments and ultimately a cure for Angelman syndrome, having invested more than $8 million during the past decade in promising AS research.

A paper published today in the Proceedings of the National Academy of Sciences by Dr. Ben Philpot, Dr. Mark Zylka and Dr. Angela Mabb at the University of North Carolina at Chapel Hill uncovered additional findings about the Angelman syndrome gene, UBE3A.


Neurotypical individuals have two copies of the Angelman syndrome gene (UBE3A), one copy inherited from their mother (the maternal copy) and one from their father (the paternal copy).  Only the maternal copy of UBE3A is “active” in neurons, thus mutation or deletion of this copy is sufficient to cause Angelman syndrome. The primary goal of the 2008 ASF Research Roadmap was to aggressively explore activation of the silenced or “inactive” paternal copy of UBE3A as a potential treatment for Angelman syndrome.


Recent studies by Dr. Ben Philpot, Dr. Mark Zylka, and Dr. Angela Mabb and their colleagues at the University of North Carolina at Chapel Hill demonstrated that Topotecan, a natural product derivative typically used to treat cancer, can unsilence the paternal copy of UBE3A. Topotecan thus represents a potential treatment for Angelman syndrome.  However, it is essential to understand the potential side effects and the impacts of using Topotecan on brain function before moving into clinical trials.  Accordingly, the studies described in this article from the Proceedings of the National Academy of Sciences continue the research group’s previous research in an effort to determine the consequences of using Topotecan or similar inhibitors in the brain.

The team took a step back from the mouse model and used an in vitro model, or neurons in a petri dish, because this provides a system to reliably and consistently deliver Topotecan to neurons.

This article illustrated that when neurons were treated with Topotecan, the goal of unsilencing the paternal copy of UBE3A was accomplished. However, during treatment, the neurons experienced a complete shutdown of activity—UBE3A was activated, but the specific cells that were treated stopped communicating with each other. However, normal neuronal activity was quickly restored once Topotecan was removed.  This result is exciting because it suggests that most treatment side effects are likely to be fully reversible.

A goal of the research is to find a treatment strategy that can provide long-term UBE3A unsilencing, as was observed with their previous research, such that the side effects of Topotecan can be completely recovered in the short-term, as was observed in the current study.

The next step to this research is to identify novel and more efficient delivery methods using Topotecan or other inhibitors like Topotecan in an AS animal model to unsilence UBE3A, to evaluate potential side effects of these treatments, and to see if Angelman syndrome symptoms in the mouse model can be reversed following drug treatment.
Click here to access the PNAS paper.

22 Oct

ASF invests $1.5 million to support 17 Angelman Syndrome Clinics across the U.S.

Furthering its direct support of individuals with Angelman syndrome and their families, the Angelman Syndrome Foundation has committed $1.5 million to establish 17 comprehensive Angelman Syndrome Clinics across the country during the next few years. The ASF has strategically identified locations that are within a 4-hour driving distance for more than 85% of the AS population in the U.S.—meaning a majority of families (>85%) in the U.S. will not have to travel more than four hours to access their nearest clinic, which is a primary goal of the ASF’s in making the clinics as accessible as possible. Each clinic will receive a three-year funding commitment of $50,000 the first year, $30,000 the second year, and $10,000 the third year, to establish the clinics and support them until they are self-sustaining.

Currently, there are two Angelman Syndrome Clinics established in Chapel Hill, NC and Boston, MA. The ASF is in the final stages to open the next clinic in Rochester, MN and has requested proposals to establish the next clinics in San Diego and Houston, with Chicago to follow. In alphabetical order, future target cities include Atlanta, Cleveland, Dallas, Denver, Jacksonville, New York, Philadelphia, Salt Lake City, San Francisco, Seattle and St. Louis.

The purpose of the ASF’s Angelman Syndrome Clinics is to:

  • Provide a “one-stop-shop” medical and psychosocial resource from birth through adulthood for individuals with AS
  • Provide a foundation to support future clinical trials by having established sites with AS experts and patients in place to conduct those trials when they become available
  • Provide access to a variety of individuals all specializing in AS:  clinical geneticist, neurologist, psychiatrist, psychologist, speech language pathologist, physical/occupational therapist, genetic counselor, social worker, and nutritionist

Learn more about the Angelman Syndrome Clinics and current locations.

Annual Tractor Cruise Supports ASF
29 Sep

Olsen Tractor Cruise 2014

Olsen FamilyEvery year, the Olsen Family—Keith, Denise and their children—hosts a Tractor Cruise fundraiser in support of the Angelman syndrome community. Held on Labor Day, this year’s cruise featured nearly 40 tractors that proceeded on a 40-mile trip on Brown County, Kansas roads. With beautiful weather for everyone to enjoy during the whole day, the group took a lunch break at the local Agricultural Museum, where the Brown County Historical Society helped serve a delicious meal for the cruisers—it was so good, there were no leftovers!

This is the ninth year that the Olsen’s have hosted the Tractor Cruise, and collectively have raised more than $25,000 in support of the AS community over the years! The Olsen’s are looking forward to the 10th anniversary Tractor Cruise next year during Labor Day weekend, which will also kick-off at Everest Middle School in Everest, Kansas.

Many thanks to the Olsen’s and their friends, family and supporters for their incredible support of our loved ones with AS!

Click here for more photos of the 2014 Tractor Cruise—it was a fun time had by all!

09 Jan

AS research at Baylor University Seeking Viable Treatment Makes Significant Progress

The Angelman Syndrome Foundation and the lab of Arthur Beaudet, M.D., at Baylor University are inspired and excited to announce that progress is being made in analyzing a possible avenue of treatment for Angelman syndrome.

The research, funded by the Angelman Syndrome Foundation in the organization’s 2011 and 2013 research grant cycles, seeks to find a possible treatment for Angelman syndrome by activating the paternal copy of Ube3a in a mouse model.

Ongoing research and this latest discovery, published in December in PLOS Genetics, have demonstrated the feasibility of activating paternal Ube3a in mice by terminating the transcription of its antisense RNA Ube3a-ATS genetically.  In doing this in the AS mouse model, the research team observed restoration of Ube3a expression, improvement of behavioral defects, and reversal of the impaired long-term potentiation.  The research team further studied the imprinting mechanisms of Ube3a and proposed a novel transcriptional collision model.  These results provide evidence for a key regulatory role of Ube3a-ATS in Angelman syndrome, opening up an exciting possibility of a gene-specific treatment for Angelman syndrome.

“We at Angelman Syndrome Foundation are optimistic about the future of this research, as our ultimate goal is finding viable treatments and a cure for our loved ones with Angelman syndrome,” said Eileen Braun, executive director of the Angelman Syndrome Foundation.  “Our Scientific Advisory Committee goes through a rigorous process in evaluating research projects for potential grants, and we are all thrilled with the results coming from the Beaudet lab.  We are incredibly appreciative of the Baylor team’s dedication to creating a better future for individuals with Angelman syndrome.”

For more information about the research or the Angelman Syndrome Foundation’s 2013 research grants, please click here.

28 Aug

University of North Carolina-Chapel Hill Research Overview and Frequently Asked Questions

The Angelman Syndrome Foundation previously supported breakthrough research showing that topoisomerase inhibitors—specifically, topotecan, an FDA-approved drug used in cancer treatments—activates the paternal allele of Ube3a, identifying a possible treatment for Angelman syndrome. The continuation of that research at the University of North Carolina-Chapel Hill has extended the possibility of using topoisomerase inhibitors to treat individuals with Angelman syndrome, and has also identified possible side effects of these drugs on the developing brain. This research is the first to show that topoisomerase inhibitors unsilence Ube3a both in a mouse model and, because of collaborative work with Dr. Stormy Chamberlain at the University of Connecticut, in stem cell-derived neurons from an individual with Angelman syndrome (deletion positive). This study thus demonstrates how Ube3a can be reactivated in patient-derived neurons. The researchers also found that in the process of activating the paternal copy of Ube3a, topotecan reduced the levels of other genes that are linked to autism, which has the potential to result in characteristics of autism in individuals. This research suggests there may be trade-offs in using these drugs to unsilence Ube3a in individuals with Angelman syndrome, and could provide insights into why mutations in topoisomerases are linked to autism. This research also highlights the continued importance of defining a critical treatment window for topoisomerase inhibitors, to determine when these drugs have their best chance of being effective while minimizing side effects on the developing brain. Most importantly, this study highlights the importance of supporting rigorous preclinical research on topoisomerase inhibitors, or any other drugs, prior to advancing into clinical trials for individuals with Angelman syndrome. Access the abstract published in Nature,

Frequently Asked Questions

1. What is Angelman syndrome’s correlation to autism and how are they linked already?

  • While some doctors, scientists and researchers do and some do not consider Angelman syndrome to be an Autism Spectrum Disorder (ASD), all can agree that there is, to a certain extent, a connection between the two. What is known so far is that:
    • Not enough or improper function of the Ube3a gene = Angelman syndrome
    • Too much functionality of the Ube3a gene = ASD
  • A few developmental and behavioral characteristics do overlap between Angelman syndrome and ASD, yet the main behavioral differentiator is that individuals with Angelman syndrome do not feel the extreme aversion to social situations as do individuals with ASD.
  • Individuals with Angelman syndrome are able to read facial expressions, body language and vocal intonations extremely well, and as a result, they enjoy and seek out social interaction.

2. How are topoisomerase inhibitors linked to autism?

  • Topoisomerase inhibitors activate the paternal copy of the Ube3a gene but in doing so, they also reduce the levels of other genes linked to autism. It is currently unknown if this could result in characteristics of autism in individuals. With proper timing, it may be possible to activate Ube3a while minimizing side effects associated with reducing the levels of genes linked to autism.
  • The effects on autism genes were only present for as long as the topoisomerase inhibitors were present; once the drug wore-off, gene expression returned to baseline levels. However, it is important to note that mutations in topoisomerases have surfaced in some individuals with autism, suggesting that an alteration in the activity of these enzymes increases the risk for autism. This further suggests it may be possible to time drug administration to minimize side effects during critical periods of brain development.

3. Why is the Angelman Syndrome Foundation funding this research?

  • The Angelman Syndrome Foundation was the first to fund this pioneering research at UNC in 2009. This research identified 16 different topoisomerase inhibitors that could unsilence paternal Ube3a, making these the first potential treatments for Angelman syndrome. This was also the first research to show that the paternal Ube3a could be unsilenced, paving the way for all future efforts to reactivate this gene that is linked to Angelman syndrome.
  • As the research study continued to progress and illustrate promising results, UNC applied for funding to continue the research, and the Angelman Syndrome Foundation awarded a research grant for its continuation (in addition to other organizations providing funding as well).
  • The Angelman Syndrome Foundation will continue to fund this research as part of its 2013 research grant cycle to determine the treatment window and autism-related side affects of topoisomerase inhibitors as a potential treatment for Angelman syndrome.

4. How could this research impact my individual who has Angelman syndrome, or for my individual who has a dual diagnosis of Angelman syndrome and autism?

  • Currently, topoisomerase inhibitors, while having shown potential, are not currently used to treat individuals with Angelman syndrome. As with any new or repurposed drug, extensive preclinical and clinical work must be done to establish safety and efficacy.
  • This research is still in pre-clinical phase and more work is being done before it has the potential to move to a clinical trial.

5. What are the next steps?

  • The research team is currently identifying the potential critical window for treatment, and what factors are involved within that critical window: identifying when topoisomerase inhibitors have their best chance of being effective, and if and when topoisomerase inhibition increases susceptibility to autism.

6. If we don’t get a “cure” from this research, then what are we getting from this research?

  • This research provides the first evidence that a drug can be used to turn on the paternal copy of Ube3a. Restoring Ube3a levels represents a critical path towards any cure or treatment for Angelman syndrome. Prior to this research, most would have thought it impossible to reactivate a silenced gene. Angelman Syndrome Foundation-funded research has shown that the impossible can be done, by supporting rigorous science and scientists who are truly committed to helping individuals with Angelman syndrome.
  • This research has spurred many other investigators to identify additional drugs that reactivate Ube3a, including promising work with antisense oligonucleotides that specifically target the antisense transcript that topoisomerase inhibitors regulate. As with topoisomerase inhibitors, there will likely be the need for numerous studies that define the optimal treatment window to ensure the drugs reach their intended target in the brain.
  • This research is beneficial to the overall Angelman syndrome community because it has identified possible side effects from using topoisomerase as a potential treatment for Angelman syndrome before this moves to clinical trial.

7. How much did the Angelman Syndrome Foundation fund for this endeavor, and how much will the organization continue to fund?

  • The Angelman Syndrome Foundation originally funded $199,972 for the initial research project in 2009.
  • UNC applied for continued funding for this project in 2011 and received $510,000 collectively in funding from the ASF’s 2011 Research Grants. These funds were awarded in two two-year grants of $200,000 each to Dr. Mark Zylka and Dr. Ben Philpot, with an additional $110,000 awarded to Dr. Ian King as part of the Angelman Syndrome Foundation’s Joseph E. Wagstaff Postdoctoral Fellowship.
  • UNC applied again in 2013 to continue this promising research, and the Angelman Syndrome Foundation continued to fund this research as part of its 2013 research grant cycle to determine the treatment window and the possible side affects of using topoisomerase inhibitors as a potential treatment for AS. These funds were awarded in two two-year grants of $200,000 each to Dr. Mark Zylka and Dr. Ben Philpot, with an additional $110,000 awarded to Dr. Angela Mabb as part of the Angelman Syndrome Foundation’s Joseph E. Wagstaff Postdoctoral Fellowship.
  • If UNC decides to apply for the ASF’s 2014 research grants for additional funds for this or other AS-related research, the ASF would evaluate that research proposal at that time.

This study is one of several ASF research initiatives that investigate potential treatments for AS. In addition to exploring topoisomerase inhibitors, the ASF is currently funding research that studies the ability of antisense to awaken the paternal Ube3a gene and the optimal time to administer treatment.

18 Jun

Angelman Syndrome Foundation Invests $1.25 Million in Research

The Angelman Syndrome Foundation (ASF) announced today that because of the generosity of its supporters the organization has awarded $1.25 million to six research grants focused on finding treatments and defining the optimal window for treatment for individuals with Angelman syndrome, a neurodevelopmental disorder which can be similar to autism.  ASF leadership approved $250,000 more than the original $1 million call for research proposals earlier this year due to the nature of the research studies and their potential impact on all ongoing Angelman syndrome, autism and other developmental disorder-related research.

“Angelman syndrome research continues to edge closer and closer to potential life-changing treatments and opportunities for individuals with Angelman syndrome, and it is because of the tremendous support of our community that the ASF is able to invest in these important research endeavors that are quintessential to the success of all future AS preclinical and clinical trials,” said Tim McCarty, president of the ASF board of directors.  “The ASF’s Scientific Advisory Committee and leadership team have evaluated these research projects thoroughly and are confident in the direction they advance Angelman syndrome research, while also furthering the advancement of related neurodevelopmental disorders including autism.  Families, friends, loved ones and others close to individuals with Angelman syndrome who have supported the ASF during our National Walk and other times of the year have made this research investment possible.”

In evaluating this year’s research proposals, the ASF Board of Directors and Scientific Advisory Committee focused on proposals that sought to discover new therapeutics for Angelman syndrome or to better understand the scientific complexities of Angelman syndrome.  This year’s Angelman syndrome research grants are significant as they seek to further define the optimal age at which to administer treatment, or the treatment window, and they further test an already FDA-approved drug as being a viable overall treatment for Angelman syndrome.

The breadth and depth of ongoing Angelman syndrome research, which is leading closer towards a cure, makes available the opportunity for this year’s funded research projects to also further the understanding of varying UBE3A gene mutations and deletions, the causative gene in Angelman syndrome.  Additionally, this year’s funded research seeks to further understand learning and memory deficits in individuals with Angelman syndrome and how they impact individuals genetically and behaviorally.

“Not all individuals with Angelman syndrome have the same genetic blueprint that causes the symptoms of Angelman syndrome, which is also why our leadership team believed that each of these research projects is important,” said Eileen Braun, executive director of the ASF.  “We want to more fully understand and be able to treat what is causing the symptoms of Angelman syndrome in each individual and help improve his or her quality of life.  The strides that research in recent years has made sets an excellent stage to build upon and we are optimistic about the direction of this year’s funded research and the further building blocks it will create.”

Research grants were awarded to:

  • Ben Philpot, Ph.D. of University of North Carolina–Chapel Hill, and Ype Elgersma, Ph.D. of Erasmus Medical Center, Rotterdam, Netherlands
  • Arthur Beaudet, M.D. and Linyan Meng, Ph.D. of Baylor College of Medicine, Houston, Texas
  • John Lisman, Ph.D. of Brandeis University, Boston, Mass.
  • Jason Shepherd, Ph.D. of University of Utah, Salt Lake City, UT
  • Craig Erickson, M.D., of Cincinnati Children’s Hospital Medical Center
  • Mark Zylka, Ph.D. of University of North Carolina–Chapel Hill


The Angelman Syndrome Foundation’s mission is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties.  As the largest non-governmental funder of Angelman syndrome research, the ASF sponsors Angelman syndrome research through grants to researchers pursuing promising avenues of discovery.  Since 1996, the ASF has funded 72 research grants totaling more than $5.8 million.  The ASF has awarded a majority of these funds ($5.5 million) beginning in 2005.